Rutgers University Department of Biomedical Engineering

July 05, 2008

Home Intro People Education Research Industry News RU Home

Biomedical Engineering Industrial Advisory Board

The IAB, comprised of senior executives from both small and large pharmaceutical and biomedical technology companies, assists in the academic leadership of the department in several ways: programmatic direction, student employment and continuing education, and technology transfer. The IAB directly influences the general education and research programs of the Department, and ensures that the needs, insights, and objectives of industry are understood by our faculty and students.

Industrial Advisory Board Members

Dr. Barry Buckland Vice President Bio-Processing Research and Development	Merck Research Laboratories Rahway, NJ
Dr. Gary Cleary Vice President and CTO	Corium International, Incorp. Redwood City, CA
Mr. Mir Imran President	In•Cube , Inc. Menlo Park, CA
Dr. Joseph LiBrizzi Manager, Product Design	Johnson and Johnson Skillman, NJ
Dr. Ramona Lloyd Vice President of Global Regulatory Services	Bristol Myers Sqibb Princeton, NJ
Dr. Mark P. Ohan Product Specialist Medical Products Division	W.L. Gore Associates, Inc. Flagstaff, AZ
Dr. William Olson Vice President Research and Development	Progenics Pharmaceutical Tarrytown, NY
Dr. Dale Peterson Science Director	The Vertical Group Summit, NJ
Dr. Scott Rakstraw Director, New Ventures	Orchid Biosciences Princeton, NJ
Dr. Joseph Reiser President and CEO	Cytogen Corporation Princeton, NJ
Dr. Greg Russotti Senior Research Engineer	Merck & Company Rahway, NJ
Dr. Peter Salmon Director Bioprocessing R&D	Merck & Company Rahway, NJ
Dr. Fred Senatore Senior Director, Executive Director	Sankyo Pharmaceuticals Edison, NJ
Dr. Steven Shaya Vice President, Corporate Office of Science & Technology	Johnson & Johnson New Brunswick, NJ
Dr. Srikanth Sundaram Program Director	Schering-Plough Corporation Kenilworth, NJ
Dr. Kambiz Shekdar Director, Product Development	Chromocell Corporation New Brunswick, NJ
Dr. Michael Smith CEO	General Devices Ridgefield, NJ
Dr. Kris Venkat Chairman	MorphoChem Monmouth Junction, NJ
Dr. Howard Weintraub Vice President of Research	C.H. Bard, Inc. Murry Hill, NJ
Dr. Michael Yamin Director: Technology Development	Warren Pharmaceuticals, Inc. New Brunswick, NJ
Dr. Youseph Yazdi Corporate Director	Johnson & Johnson New Brunswick, NJ
Dr. Mark Zimmerman Executive Director	Lifescan, Inc. Skillman , NJ

Contribute

Contribute to Biomedical Engineering at Rutgers.

Click here for more information.

Login

Latest News

Li Cai Awarded Busch Biomedical Research Grant
July 01, 2008
Li Cai received a two year $50,000 Busch Biomedical Research Grant to support his research on "Control of CD44 Expression in Breast Cancer Stem Cells". The project is to study the transcription regulation of breast cancer stem cells.

Annual Review of Biomedical Engineering Ranked No. 1 again by ISI
June 23, 2008
For the sixth year in a row, articles in the Annual Review of Biomedical Engineering (ARBME) were cited more often than papers in any of its peer journals, according to ISI's 2007 Journal Citation Report, giving it the highest "impact factor" in its peer group. The ARBME had an impact factor of 11.567 placing it #1 in its peer group of 44 journals, and #2 among all engineering journals. Professor Martin Yarmush serves as the editor-in-chief of the ARBME which published its first volume in 1999.

John Semmlow awarded $750,000 NIH-NIHLB Grant
June 13, 2008
John Semmlow and SonoMedica, Inc. of McClean, VA were awarded a Phase II STTR grant of $750,000 from the NIH-NIHLB over two years to advance his work on detection of coronary artery disease using acoustic information.

Anant Madabhushi awarded $260,000 Wallace H. Coulter Grant
June 11, 2008
Anant Madabhushi has been awarded a 2 year Phase 2 grant for $260,000 from the Wallace H. Coulter foundation for his proposal entitled "Automated Detection of Prostate Cancer from Multi-protocol High Resolution MRI". The Phase 2 award was competitive and of the 25 Phase 1 Early Career awardees only 7 were selected for Phase 2 based on progress made in Phase 1, a new grant application, and an oral presentation in front of a review committee in Florida, in early June. Under the Phase 2 project, Dr. Madabhushi will look to commercialize his ongoing research in developing computerized detection methods for prostate cancer using MRI. Clinical collaborators on this project are Dr. John Tomaszewski, Dr. Mark Rosen, and Dr. Mike Feldman from the University of Pennsylvania.

More News >>

Rutgers, The State University of New Jersey